Novel Therapeutics Directed to Intracellular HIV Targets (R21 Clinical Trial Not Allowed)

Archived

National Institutes of Health

Description

The purpose of this Funding Opportunity Announcement (FOA) is to support the development of novel therapeutics which are directed to intracellular HIV targets. During the HIV life cycle multiple viral associated proteins are expressed in the infected cell. All are critical to support assembly, release and maturation of the virus. Considering each protein has a defined role in the life cycle, therapeutically targeting one or more may be an effective strategy to obtain potent antiviral activity.

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public and State controlled institutions of higher education
  • Native American tribal governments (Federally recognized)
  • Public housing authorities / Indian housing authorities
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Private institutions of higher education
  • For-profit organizations other than small businesses
  • Small businesses
  • Others

Contact

NIH OER Webmaster <br/>FBOWebmaster@OD.NIH.GOV
FBOWebmaster@OD.NIH.GOV

Key dates & funding
  • PostedDec 19, 2019
  • ClosesJul 1, 2020
  • Program funding$3,000,000
  • CFDA93.855
Categories

Pro insight

Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.

Unlock with Pro